On Friday, Western Digital Corp (NASDAQ:WDC)’s shares declined -1.75% to $84.45.
Western Digital® Corp. (WDC) declared that it will take part in the following investor event:
Event:
Nasdaq 32nd Investor Program
When:
Tuesday, June 30 at 2:15AM Pacific / 5:15AM Eastern / 10:15AM London
Western Digital Corporation, through its auxiliaries, develops, manufactures, and sells data storage solutions that enable consumers, businesses, governments, and other organizations to create, manage, experience, and preserve digital content. It provides hard disk drives (HDDs) and solid-state drives for desktop and notebook personal computers (PCs), and performance enterprise and capacity enterprise markets. The company also offers HDDs used in consumer electronics, such as DVRs, gaming consoles, security surveillance, systems, set top boxes, camcorders, multi-function printers, and entertainment and automobile navigation systems. In addition, it provides HDDs embedded into WD, HGST, and G-Technology branded external storage appliances with capacities ranging from 500 GB to 24 TB, in addition to using various interfaces, such as USB 2.0, USB 3.0, external SATA, FireWire, Thunderbolt, and Ethernet network connections. The company sells its products to computer manufacturers, resellers, and retailers worldwide.
Automatic Data Processing (NASDAQ:ADP)’s shares dropped -0.05% to $83.31.
Automatic Data Processing, Inc. (ADP) a leading global provider of Human Capital Administration (HCM) solutions, will release the June 2015 findings of the ADP National Employment Report, ADP Small Business Report and ADP National Franchise Report on Wednesday, July 1, at 8:15 a.m. ET.
Due to the important contribution that small businesses make to economic growth, ADP issues the ADP Small Business Report independently of the ADP National Employment Report. The ADP Small Business Report offers detailed private sector employment data that are specific to businesses with 49 or fewer employees.
Automatic Data Processing, Inc., together with its auxiliaries, provides technology-based outsourcing solutions to employers worldwide. The company operates through Employer Services and Professional Employer Organization (PEO) Services segments. The Employer Services segment offers a range of business outsourcing and human capital administration (HCM) solutions, counting payroll services, benefits administration services, talent administration solutions, human resources administration solutions, time and attendance administration solutions, insurance services, retirement services, and tax compliance and payment solutions.
At the end of Friday’s trade, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)‘s shares surged 1.02% to $6.96.
Spectrum Pharmaceuticals ( SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, declared recently the publication of results from the pivotal BELIEF (CLN-19) Study, which was selected as a Rapid Communication in the Journal of Clinical Oncology (JCO), the journal of the American Society of Clinical Oncology. The study, led by Dr. Owen O’Connor from the Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY, showed that monotherapy with Beleodaq produced complete and durable responses with manageable toxicity in patients with R/R PTCL across the major subtypes, irrespective of the number or type of prior therapies.
Beleodaq, formerly known as belinostat, is a histone deacetylase (HDAC) inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor Response Rate and Duration of Response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company markets five drug products, counting FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with follicular non-Hodgkins lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; and BELEODAQ injection for patients with relapsed or refractory PTCL.
ARM Holdings plc (ADR) (NASDAQ:ARMH), ended its Friday’s trading session with -5.33% loss, and closed at $50.99.
ARM Holdings plc (ADR) (ARMH) has signed an expansive long-term graphics technology agreement with Samsung to enable the creation of next generation devices capable of delivering even more compelling visual experiences. The subscription license covers ARM® Mali™ graphics processing units (GPUs) counting the Mali-T820/830/860, the recently declared Mali-T880 and all future Mali GPUs.
This long term contract with ARM allows Samsung to continue creating innovative products addressing a range of price and performance points to meet the evolving needs of multiple markets. Samsung is already utilizing ARM Mali technology in SoCs powering an impressive range of leading consumer products.
ARM Holdings plc, together with its auxiliaries, designs microprocessors, physical intellectual property (IP), and related technology and software. The company also sells development tools that enhance the performance of embedded applications. Its products comprise microprocessor cores that comprise of specific functions, such as video, graphics, and display technology IP; and physical IP components for the design and manufacture of integrated circuits, which comprise embedded memory, standard cell, and input/output components.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
